Evidence map›Paper›PMID 30070930›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2018

Pyrrolo[3,2-c]pyridine derivatives with potential inhibitory effect against FMS kinase: in vitro biological studies.

Mohammed I El-Gamal, Chang-Hyun Oh

Abstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Design, synthesis, and bioevaluation of 1Journal of enzyme inhibition and medicinal chemistry · 2024
    Article
  3. POClRSC advances · 2023
    Article
  4. Potential Stereoselective Binding ofMolecules (Basel, Switzerland) · 2022
    Article
  5. An Overview of the Biological Activity of Pyrrolo[3,4-Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  6. Bioactive pyrrole-based compounds with target selectivity.European journal of medicinal chemistry · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mohammed I El-Gamala Department of Medicinal Chemistry, College of Pharmacy , University of Sharjah , Sharjah , United Arab Emirates.ORCID http://orcid.org/0000-0002-4269-5264
Chang-Hyun Ohd Center for Biomaterials, Korea Institute of Science and Technology , Seoul , Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of eighteen pyrrolo[3,2-c]pyridine derivatives were tested for inhibitory effect against FMS kinase. Compounds 1e and 1r were the most potent among all the other tested analogues (IC

Indexed as

BenzamidesCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorFemaleHumansInhibitory Concentration 50MacrophagesMaleProtein Kinase InhibitorsPyridinesPyrrolesReceptor, Macrophage Colony-Stimulating FactorBenzamidesN-(3-(4-benzamido-1H-pyrrolo(3,2-c)pyridin-1-yl)phenyl)-4-morpholino-3-(trifluoromethyl)benzamideProtein Kinase InhibitorsPyridinesPyrrolespyrrolo(3,2-c)pyridineReceptor, Macrophage Colony-Stimulating FactorCSF-1RFMSkinase inhibitionpyrrolo[3,2-c]pyridine

Identifiers

PMID30070930
PMCPMC6084503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.